Cell Culture Media Market by Type (Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application (Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User (Pharma, Biotech) & Region - Global Forecast to 2026
Updated on : May 04, 2023
The global cell culture media market in terms of revenue was estimated to be worth $4.9 billion in 2021 and is poised to reach $10.3 billion by 2026, growing at a CAGR of 16.0% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalised medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth of this market.
To know about the assumptions considered for the study, Request for Free Sample Report
Cell Culture Media Market Dynamics
Driver: Emerging cell culture technologies for cell-based vaccines
In the pharmaceutical industry, cell culture has become a prominent part of vaccine production. The cell culture technology has been used to produce vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox. Cell-based flu vaccines have also been approved for use in the US and many European countries.
Earlier, vaccines were manufactured by growing and harvesting viruses in chicken eggs, which was a time-consuming process. On the other hand, cell culture-based vaccine production is a far more efficient method. Its advantages over traditional manufacturing methods include a shortened lead time and the capability to produce vaccines in larger quantities as demand dictates. Moreover, cell culture-based vaccines can be stored for a longer period of time. According to a study published by the CDC in the June 2020 issue of the Journal of Infectious Diseases, cell-based vaccines provided greater protection against flu-related hospitalisations than standard-dose egg-based vaccines among Medicare beneficiaries 65 years of age and older. For the 2020–2021 flu season, all four flu viruses used in Flucelvax Quadrivalent were cell-derived. Consequently, recent years have seen a surge in cell-based vaccines, resulting in efforts by prominent companies to capitalise on the opportunities provided. Seqirus, for example, has been active in this field.
- In February 2020, Seqirus (a part of CSL Limited) received US FDA approval for AUDENZ, a cell-based Influenza A (H5N1) Monovalent Vaccine for individuals aged six months and older.
- In January 2019, Seqirus received approval from the European Commission for its new cell-based seasonal influenza vaccine, FLUCELVAX TETRA.
- In October 2018, Seqirus secured FDA approval for a next-generation cell-based influenza vaccine manufacturing process. This approval has enabled the inclusion of children as young as 6 months. Also, after the FDA approval for its cell-based manufacturing technology, Seqirus went from producing 3 million doses in 2015 to 20 million doses in 2020.
Since there is a surge in demand for cell culture-based vaccines, new techniques for vaccine development are emerging. This has subsequently boosted the demand for cell culture media.
Restraint: Ethical concerns regarding cell biology research
Research in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs, which may harm animals and humans. In addition, stem cell research studies use human embryos for clinical applications that often lead to the destruction of human embryos. In order to monitor these activities, strict regulations have been formulated by ethical authorities in various countries across the globe. Authorities such as the Human Tissue Authority (HTA), the Human Fertilization and Embryology Authority (HFEA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and the Central Ethics Committee for Stem Cell Research (ZES), among others, have implemented stringent regulations for cell biology research. These ethical concerns and restrictions on the use of cells for research are limiting cell biology research to a great extent in various countries across the globe. This, in turn, is expected to restrict the demand for cell culture products, including cell culture media.
Opportunity: Emerging markets
During the forecast period, emerging countries such as China, India, Brazil, and Mexico are expected to become the focal point for growth in the global market. Increasing investments in cell biology research and the rising focus of market players on increasing their presence in emerging Asian markets are the major factors responsible for this trend.
Several market players are investing in the development of cell-based research facilities in emerging Asian countries, primarily due to the increasing prevalence of chronic diseases, improvements in infrastructural facilities for research, and favorable legislation for cell-based research. Furthermore, India is an attractive destination for companies operating in the global market, primarily due to the rising government investments for building high-tech infrastructure for cell-based research, the presence of highly skilled labor, and the low-cost manufacturing advantage. The Indian Department of Pharmaceuticals has prepared a “Pharma Vision 2020” document for making India a leading destination for drug discovery and innovation. Through this, the government provides support in terms of setting up world-class infrastructure, creating an internationally competitive scientific workforce for pharma R&D, and supporting venture funding for public and private research. Similarly, according to a report published by the US-China Economic and Security Review Commission, the Government of China invested USD 311 million and USD 420 million in stem cell research as a part of the 12th Five Year Plan (FYP) and the 13th FYP, respectively. In regard to follow-up implementation guidance published in 2017, Shanghai determined five areas as its developmental priorities, including bioproduct manufacturing, drug development & innovation, biotech industrialization, contract research activities, and global supply chain building. Considering these benefits, biopharmaceutical and pharmaceutical companies are increasingly focusing on drug discovery outsourcing to countries such as India and China, which is driving the adoption of cell culture media products in research applications.
Countries such as Brazil and Mexico are also expected to offer significant growth opportunities for players operating in the global market. The booming biopharmaceutical sector in these countries, increased risk of pandemics (such as swine flu and COVID-19), less-stringent regulatory guidelines, and the low manufacturing cost advantage are the major factors that are attracting market players to set up and expand their presence in these countries.
Challenge: Survival of small players and new entrants
The survival of small players and new entrants in the global market is a significant challenge. Established players such as Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group AG (Switzerland), Sartorius AG (Germany), and Danaher Corporation (US) account for a major share of the market. These players have a robust product portfolio and strong brand recognition. In addition, these key players tend to maintain their competitive advantage by acquiring new entrants or start-ups with an aim to boost their product portfolio. For instance, in July 2021, Sartorius AG acquired cell culture specialist Xell AG (Germany) with a focus on media for gene therapeutics and vaccines. This helped the company to expand its capabilities for manufacturing dry powder and liquid media.
Considering the strong presence of major players, it is difficult for small players and new entrants to compete in this market. Also, as large investments are required for the R&D and launch of innovative products, it is difficult for small players to sustain their operations and compete with established players that have large R&D budgets.
The serum-free media subsegment of the type segment dominated Cell Culture Media Market
The global market, by type, is segmented into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest region of the global cell culture media market.
The global market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the global market, followed by Europe. The growing regulatory approvals for cell culture-based vaccines, growth in the biotechnology & pharmaceutical industries, higher investments in cell-based research, and strong government support are the key factors driving the growth of the market in North America.
Key players in the Cell Culture Media Market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US).
Cell Culture Media Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$4.9 billion |
|
Projected Revenue by 2026 |
$10.3 billion |
|
Revenue Rate |
poised to grow at a CAGR of 16.0% |
|
Market Driver |
Emerging cell culture technologies for cell-based vaccines |
|
Market Opportunity |
Emerging markets |
This report categorizes the cell culture media market to forecast revenue and analyze trends in each of the following submarkets:
By Type
- Serum-free Media
- CHO Media
- HEK 293 Media
- BHK Media
- VERO Cell Media
- Insect Cell Media
- Serum-free Stem Cell Media
- CAR T-cell Media
- Other Serum-free Media
- Classical Media & Salts
- Stem Cell Culture Media
- Specialty Media
- Chemically defined Media
- Other Cell Culture Media
By Application
- Biopharmaceutical Production
- Monoclonal antibodies
- Vaccines production
- Other therapeutic proteins
- Diagnostics
- Drug Screening & Development
- Tissue Engineering & Regenerative Medicine
- Cell and gene therapy
- Other tissue engineering & regenerative medicine applications
- Other Applications
By End user
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Research & Academic Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
-
Latin America (LATAM)
- Brazil
- Mexico
- RoLATAM
- Middle East and Africa (MEA)
Recent Developments
- In October 2021, Thermo Fisher Scientific Inc. (US) launched the Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, which supports the large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells.
- In July 2021, Sartorius AG acquired cell culture specialist Xell AG thus expanding its capabilities for manufacturing dry powder and liquid media.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the cell culture media market?
The cell culture media market boasts a total revenue value of $10.3 billion by 2026.
What is the estimated growth rate (CAGR) of the cell culture media market?
The global cell culture media market has an estimated compound annual growth rate (CAGR) of 16.0% and a revenue size in the region of $4.9 billion in 2021.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 39)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 43)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: CELL CULTURE MEDIA MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 GLOBAL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2020
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 GLOBAL MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 7 GLOBAL MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 54)
FIGURE 9 CELL CULTURE MEDIA MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 58)
4.1 CELL CULTURE MEDIA MARKET OVERVIEW
FIGURE 13 RISING R&D SPENDING IN PHARMA COMPANIES AND EMERGING CELL CULTURE TECHNOLOGIES FOR CELL-BASED VACCINES WILL DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY TYPE AND COUNTRY (2020)
FIGURE 14 SERUM-FREE MEDIA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 GLOBAL MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 15 BIOPHARMACEUTICAL PRODUCTION SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 GLOBAL MARKET, BY END USER, 2020 (USD MILLION)
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED THE MARKET IN 2020
4.5 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH IN THE GLOBAL MARKET FROM 2021 TO 2026
5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 GLOBAL MARKET: DRIVERS, RESTRAINT, OPPORTUNITIES, AND CHALLENGES
TABLE 1 GLOBAL MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising R&D spending in pharmaceutical companies
FIGURE 19 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
5.2.1.2 Emerging cell culture technologies for cell-based vaccines
TABLE 2 APPROVED CELL CULTURE-BASED VACCINES FOR INFLUENZA
5.2.1.3 Increasing demand for monoclonal antibodies
TABLE 3 APPROVED MONOCLONAL ANTIBODIES BY US FDA FOR THERAPEUTIC USE
5.2.1.4 Growth in stem cell research
5.2.1.5 Launch of new cell culture media products by market players
5.2.1.6 Growing focus on personalized medicine
TABLE 4 GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES
FIGURE 20 GROWING NUMBER OF FDA APPROVALS FOR PERSONALIZED MEDICINES
5.2.2 RESTRAINTS
5.2.2.1 Expensive cell biology research products
5.2.2.2 Ethical concerns regarding cell biology research
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in 3D cell culture
5.2.3.2 Increasing incidence of infectious diseases and outbreaks of pandemics
5.2.3.3 Emerging markets
5.2.4 CHALLENGES
5.2.4.1 Survival of small players and new entrants
5.3 RANGES/SCENARIOS
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE GLOBAL MARKET
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22 REVENUE SHIFT & NEW REVENUE POCKETS FOR CELL CULTURE MEDIA PROVIDERS
5.5 IMPACT OF THE COVID-19 OUTBREAK ON THE GLOBAL MARKET
FIGURE 23 GLBOAL MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021
5.6 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF DIFFERENT TYPES OF MEDIA/1000 L IN DEVELOPED AND DEVELOPING COUNTRIES (2020)
5.7 PATENT ANALYSIS
FIGURE 24 PATENT APPLICATIONS FOR THE GLOBAL MARKET, JANUARY 2011–FEBRUARY 2022
TABLE 6 INDICATIVE LIST OF PATENTS IN THE GLOBAL MARKET
5.8 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 26 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
TABLE 7 SUPPLY CHAIN ECOSYSTEM
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.12 REGULATORY ANALYSIS
5.12.1 US
5.12.2 EUROPE
6 CELL CULTURE MEDIA MARKET, BY TYPE (Page No. - 87)
6.1 INTRODUCTION
TABLE 9 GLOBAL MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.1.1 SERUM-FREE MEDIA
TABLE 10 SERUM-FREE MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 11 SERUM-FREE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 12 SERUM-FREE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 NORTH AMERICA: SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 EUROPE: SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 ASIA PACIFIC: SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 16 LATIN AMERICA: SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.1 CHO media
6.1.1.1.1 Growing adoption of CHO media in biopharmaceutical companies to drive the growth of this market segment
TABLE 17 CHO MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 18 CHO MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 19 NORTH AMERICA: CHO MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 EUROPE: CHO MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 ASIA PACIFIC: CHO MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 LATIN AMERICA: CHO MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.2 HEK 293 media
6.1.1.2.1 Advantages of HEK 293 cell lines are expected to drive the growth of this market segment
TABLE 23 HEK 293 MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 24 HEK 293 MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 25 NORTH AMERICA: HEK 293 MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 EUROPE: HEK 293 MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 ASIA PACIFIC: HEK 293 MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 LATIN AMERICA: HEK 293 MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.3 BHK media
6.1.1.3.1 BHK media have wide applications in the production of recombinant proteins
TABLE 29 BHK MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 30 BHK MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: BHK MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: BHK MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: BHK MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 LATIN AMERICA: BHK MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.4 Vero cell media
6.1.1.4.1 Increasing role of Vero cells in research pertaining to viral vaccines to drive the growth of this market segment
TABLE 35 VERO CELL MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 36 VERO CELL MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: VERO CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 EUROPE: VERO CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 ASIA PACIFIC: VERO CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 LATIN AMERICA: VERO CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.5 Serum-free stem cell media
6.1.1.5.1 Availability of funding for stem cell research driving the growth of this market segment
TABLE 41 SERUM-FREE STEM CELL MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 42 SERUM-FREE STEM CELL MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: SERUM-FREE STEM CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 EUROPE: SERUM-FREE STEM CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 ASIA PACIFIC: SERUM-FREE STEM CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 LATIN AMERICA: SERUM-FREE STEM CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.6 Insect cell media
6.1.1.6.1 Growing adoption of insect cell media for heterologous protein expression driving the growth of this market segment
TABLE 47 INSECT CELL MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 48 INSECT CELL MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: INSECT CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 EUROPE: INSECT CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 ASIA PACIFIC: INSECT CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 LATIN AMERICA: INSECT CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.7 CAR T-cell media
6.1.1.7.1 Growing demand for adoptive T-cell therapy to drive the growth of this market segment
TABLE 53 CAR T-CELL MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 54 CAR T-CELL MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 55 NORTH AMERICA: CAR T-CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 EUROPE: CAR T-CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 ASIA PACIFIC: CAR T-CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 LATIN AMERICA: CAR T-CELL MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.1.8 Other serum-free media
TABLE 59 OTHER SERUM-FREE MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 60 OTHER SERUM-FREE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: OTHER SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: OTHER SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 ASIA PACIFIC: OTHER SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 LATIN AMERICA: OTHER SERUM-FREE MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.2 CLASSICAL MEDIA & SALTS
6.1.2.1 Wide use of classical media & salts across all types of cell culture applications to drive the growth of this market segment
TABLE 65 CLASSICAL MEDIA & SALTS OFFERED BY KEY MARKET PLAYERS
TABLE 66 CLASSICAL MEDIA & SALTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: CLASSICAL MEDIA & SALTS MARKET, BY COUNTRY, 026 (USD MILLION)
TABLE 69 ASIA PACIFIC: CLASSICAL MEDIA & SALTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 70 LATIN AMERICA: CLASSICAL MEDIA & SALTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.3 STEM CELL CULTURE MEDIA
6.1.3.1 Increasing collaborations between universities and pharma-biotech companies for stem cell research to drive the growth of this market segment
TABLE 71 STEM CELL CULTURE MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 72 STEM CELL CULTURE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 76 LATIN AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.4 CHEMICALLY DEFINED (CD) MEDIA
6.1.4.1 Ability of CD media to increase reproducibility to drive the growth of this market segment
TABLE 77 CHEMICALLY DEFINED MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 78 CHEMICALLY DEFINED MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 79 NORTH AMERICA: CHEMICALLY DEFINED MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: CHEMICALLY DEFINED MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 81 ASIA PACIFIC: CHEMICALLY DEFINED MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 82 LATIN AMERICA: CHEMICALLY DEFINED MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.5 SPECIALTY MEDIA
6.1.5.1 Ability of primary cells to proliferate in specialty media is expected to fuel the growth of this market segment
TABLE 83 SPECIALTY MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 84 SPECIALTY MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 85 NORTH AMERICA: SPECIALTY MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 86 EUROPE: SPECIALTY MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 ASIA PACIFIC: SPECIALTY MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 LATIN AMERICA: SPECIALTY MEDIA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.1.6 OTHER CELL CULTURE MEDIA
TABLE 89 OTHER CELL CULTURE MEDIA OFFERED BY KEY MARKET PLAYERS
TABLE 90 OTHER CELL CULTURE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 93 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 94 LATIN AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 CELL CULTURE MEDIA MARKET, BY APPLICATION (Page No. - 127)
7.1 INTRODUCTION
TABLE 95 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 BIOPHARMACEUTICAL PRODUCTION
TABLE 96 GLOBAL MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 97 NORTH AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 98 EUROPE: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 ASIA PACIFIC: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 LATIN AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 101 GLOBAL MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
7.2.1 MONOCLONAL ANTIBODY PRODUCTION
7.2.1.1 Growing demand for monoclonal antibody production is fueling the growth of this market segment
TABLE 102 INDICATIVE LIST OF APPROVED ANTIBODY PRODUCTS PRODUCED IN CHO CELLS
TABLE 103 INDICATIVE LIST OF MONOCLONAL ANTIBODIES WITH FDA AUTHORIZATION
TABLE 104 GLOBAL MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 105 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 106 EUROPE: MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 108 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.2 VACCINE PRODUCTION
7.2.2.1 Growing government support for vaccine production to drive the growth of this market segment
TABLE 109 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
TABLE 110 CELL CULTURE MEDIA MARKET FOR VACCINE PRODUCTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 111 NORTH AMERICA: MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 112 EUROPE: MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 113 ASIA PACIFIC: MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 114 LATIN AMERICA: MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.3 OTHER THERAPEUTIC PROTEIN PRODUCTION
TABLE 115 GLOBAL MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 116 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 117 EUROPE: MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 118 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 119 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 DIAGNOSTICS
7.3.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 120 GLOBAL MARKET FOR DIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
TABLE 121 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 122 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 124 LATIN AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 DRUG SCREENING & DEVELOPMENT
7.4.1 ADOPTION OF CELL-BASED ASSAYS IN DRUG DISCOVERY WILL DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 125 GLOBAL MARKET FOR DRUG SCREENING & DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 126 NORTH AMERICA: MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 127 EUROPE: MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 129 LATIN AMERICA: MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 TISSUE ENGINEERING & REGENERATIVE MEDICINE
TABLE 130 CELL CULTURE MEDIA MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 GLOBAL MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2019–2026 (USD MILLION)
TABLE 132 NORTH AMERICA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 133 EUROPE: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 134 ASIA PACIFIC: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 135 LATIN AMERICA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2019–2026 (USD MILLION)
7.5.1 CELL & GENE THERAPY
7.5.1.1 Increasing adoption of cell and gene therapies for treating patients to fuel the growth of this market
TABLE 136 CELL CULTURE MEDIA MARKET FOR CELL & GENE THERAPY, BY REGION, 2019–2026 (USD MILLION)
TABLE 137 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 138 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 139 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 140 LATIN AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
7.5.2 OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS
TABLE 141 GLOBAL MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 143 EUROPE: MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 145 LATIN AMERICA: MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 OTHER APPLICATIONS
TABLE 146 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 147 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 148 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 149 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 150 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
8 CELL CULTURE MEDIA MARKET, BY END USER (Page No. - 157)
8.1 INTRODUCTION
TABLE 151 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING RESEARCH EXPENDITURE BY PHARMA AND BIOTECH COMPANIES WILL DRIVE THE GROWTH OF THIS SEGMENT
TABLE 152 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 153 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 154 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 155 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 156 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 HOSPITALS & DIAGNOSTIC LABORATORIES
8.3.1 INCREASING APPLICATIONS OF CELL CULTURE MEDIA IN DISEASE DIAGNOSIS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 157 GLOBAL MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 158 NORTH AMERICA: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 159 EUROPE: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 160 ASIA PACIFIC: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 161 LATIN AMERICA: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 RESEARCH & ACADEMIC INSTITUTES
8.4.1 GROWING PREVALENCE OF CANCER AND INCREASING RESEARCH FUNDING TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 162 CELL CULTURE MEDIA MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 163 NORTH AMERICA: MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 164 EUROPE: MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 165 ASIA PACIFIC: MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 166 LATIN AMERICA: MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 OTHER END USERS
TABLE 167 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 168 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 169 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 170 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 171 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
9 CELL CULTURE MEDIA MARKET, BY REGION (Page No. - 170)
9.1 INTRODUCTION
TABLE 172 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: CELL CULTURE MEDIA MARKET SNAPSHOT
TABLE 173 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 174 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 175 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 177 NORTH AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 178 NORTH AMERICA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 179 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 Growing pharmaceutical and biotechnology sector in the US to drive market growth
TABLE 180 US: CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 US: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 183 US: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 US: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Increase in stem cell research funding in Canada to fuel market growth
TABLE 186 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 CANADA: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 189 CANADA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 190 CANADA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 191 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 192 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 193 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 EUROPE: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 196 EUROPE: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 197 EUROPE: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Strong growth in the biotechnology industry in Germany to drive market growth
TABLE 199 GERMANY: , BY TYPE, 2019–2026 (USD MILLION)
TABLE 200 GERMANY: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 202 GERMANY: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 203 GERMANY: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 UK
9.3.2.1 Advancements in the life sciences sector to boost market growth in the UK
TABLE 205 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 UK: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 208 UK: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 UK: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Increase in government funding for life science research to drive market growth in France
TABLE 211 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 FRANCE: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 213 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 214 FRANCE: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 215 FRANCE: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Growing support for life science research in Italy to fuel market growth
TABLE 217 ITALY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 ITALY: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 ITALY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 220 ITALY: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 ITALY: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 222 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Advancement of translational personalized medicine to aid market growth in Spain
TABLE 223 SPAIN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 SPAIN: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 225 SPAIN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 226 SPAIN: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 SPAIN: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 229 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 230 ROE: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 232 ROE: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 ROE: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 234 ROE: MARKET, BY END USER 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 235 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 236 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ASIA PACIFIC: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 239 ASIA PACIFIC: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ASIA PACIFIC: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 241 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China to register the highest growth rate in the Asia Pacific market during the forecast period
TABLE 242 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 CHINA: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 244 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 245 CHINA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 246 CHINA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 247 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Increasing geriatric population along with rising cancer cases to drive market growth in Japan
TABLE 248 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 249 JAPAN: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 251 JAPAN: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 JAPAN: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Government support for scientific research and expansion of the pharma-biotech sector to drive market growth in India
TABLE 254 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 255 INDIA: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 256 INDIA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 257 INDIA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 258 INDIA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 259 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 260 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 ROAPAC: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 263 ROAPAC: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 264 ROAPAC: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 265 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 266 LATIN AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 267 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 268 LATIN AMERICA: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 269 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 270 LATIN AMERICA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 271 LATIN AMERICA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 272 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Expanding pharmaceutical market in Brazil to fuel market growth
TABLE 273 BRAZIL: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 274 BRAZIL: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 275 BRAZIL: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 276 BRAZIL: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 277 BRAZIL: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 278 BRAZIL: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Growth in pharmaceutical R&D and manufacturing to drive the demand for cell culture media in Mexico
TABLE 279 MEXICO: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 280 MEXICO: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 281 MEXICO: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 282 MEXICO: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 283 MEXICO: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 284 MEXICO: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 285 ROLATAM: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 286 ROLATAM: SERUM-FREE CELL CULTURE MEDIA MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 287 ROLATAM: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 288 ROLATAM: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 289 ROLATAM: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 290 ROLATAM: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST AND AFRICA
9.6.1 GROWING FUNDING INITIATIVES AND STRATEGIC PARTNERSHIPS DRIVING MARKET GROWTH IN MEA
TABLE 291 MEA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 292 MEA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 293 MEA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 294 MEA: MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 295 MEA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2019–2026 (USD MILLION)
TABLE 296 MEA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 234)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 29 KEY DEVELOPMENTS IN THE CELL CULTURE MEDIA MARKET, 2019–2022
10.3 MARKET SHARE ANALYSIS
FIGURE 30 GLOBAL MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
TABLE 297 GLOBAL MARKET: DEGREE OF COMPETITION
10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 31 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE GLOBAL MARKET, 2018–2020
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 32 GLOBAL MARKET: COMPANY EVALUATION QUADRANT, 2020
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 33 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
10.7 PRODUCT FOOTPRINT OF COMPANIES
TABLE 298 PRODUCT PORTFOLIO ANALYSIS: GLOBAL MARKET (2020)
10.8 REGIONAL FOOTPRINT OF COMPANIES
TABLE 299 REGIONAL FOOTPRINT OF COMPANIES: GLOBAL MARKET (2020)
10.9 COMPETITIVE SCENARIO
TABLE 300 PRODUCT LAUNCHES
TABLE 301 DEALS
TABLE 302 EXPANSIONS
11 COMPANY PROFILES (Page No. - 247)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 303 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
11.1.2 MERCK KGAA
TABLE 304 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2020)
11.1.3 DANAHER CORPORATION
TABLE 305 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.4 SARTORIUS AG
TABLE 306 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2020)
11.1.5 CORNING INCORPORATED
TABLE 307 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 38 CORNING INCORPORATED: COMPANY SNAPSHOT (2020)
11.1.6 FUJIFILM IRVINE SCIENTIFIC, INC. (ACQUIRED BY FUJIFILM HOLDINGS CORPORATION)
TABLE 308 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 39 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
11.1.7 LONZA GROUP AG
TABLE 309 LONZA GROUP AG: BUSINESS OVERVIEW
FIGURE 40 LONZA GROUP AG: COMPANY SNAPSHOT (2020)
11.1.8 BECTON, DICKINSON AND COMPANY (BD)
TABLE 310 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.9 MILTENYI BIOTEC
TABLE 311 MILTENYI BIOTEC: BUSINESS OVERVIEW
11.1.10 HIMEDIA LABORATORIES PVT. LTD.
TABLE 312 HIMEDIA LABORATORIES PVT. LTD.: BUSINESS OVERVIEW
11.1.11 STEMCELL TECHNOLOGIES INC.
TABLE 313 STEMCELL TECHNOLOGIES INC.: BUSINESS OVERVIEW
11.1.12 BIOLOGOS LLC.
TABLE 314 BIOLOGOS LLC.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 CELL APPLICATIONS, INC.
11.2.2 CAISSON LABORATORIES INC.
11.2.3 PROMOCELL GMBH
11.2.4 CELL BIOLOGICS, INC.
11.2.5 INVIVOGEN
11.2.6 PAN-BIOTECH GMBH
11.2.7 PEPROTECH, INC.
11.2.8 CELLULAR TECHNOLOGY LIMITED LLC.
11.2.9 ZEN-BIO, INC.
11.2.10 ATHENA ENVIRONMENTAL SCIENCES, INC.
11.2.11 CYAGEN BIOSCIENCES
11.2.12 BIOWEST SAS
11.2.13 AKRON BIOTECH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 297)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell culture media market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as the World Health Organization (WHO), American Society for Cell Biology (ASCB), American Society for Gene and Cell Therapy (ASGCT), International Serum Industry Association (ISIA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Pharmaceutical Research and Manufacturers of America (PhRMA), Department of Biotechnology (DBT), French National Research Agency, Ministry of Education, University and Research (MIUR), National Institute of Statistics (INE), Japan Agency for Medical Research and Development, Department of Regenerative Medicine and Cell and Gene Therapies, Ministry of Health and Welfare (MoHW). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global cell culture media market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global cell culture media market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the cell culture media market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the cell culture media market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the cell culture media business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Report Objectives
- To define, describe, and forecast the global cell culture media market based on type, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall cell culture media market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions; new product launches; expansions; and agreements, partnerships, and collaborations in the cell culture media market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Generating Response ...
Growth opportunities and latent adjacency in Cell Culture Media Market